The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Upgrades 2025 full-year CDMO sales and margin outlook
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
